146 related articles for article (PubMed ID: 16684800)
1. Emtricitabine intolerance in treatment-experienced patients switched from lamivudine: a method of assessing toxicity.
Pollock K; Stebbing J; Bower M; Gazzard B; Nelson M
J Antimicrob Chemother; 2006 Jul; 58(1):227-8. PubMed ID: 16684800
[No Abstract] [Full Text] [Related]
2. Emtricitabine: new preparation. An antiretroviral very similar to lamivudine.
Prescrire Int; 2005 Apr; 14(76):54-6. PubMed ID: 15875341
[TBL] [Abstract][Full Text] [Related]
3. The art of managing human immunodeficiency virus infection: a balancing act.
Reiss P
Clin Infect Dis; 2009 Nov; 49(10):1602-4. PubMed ID: 19842978
[No Abstract] [Full Text] [Related]
4. Combination antiretroviral therapy with tenofovir, emtricitabine or lamivudine, and nevirapine.
Redfield RR; Morrow JS
Clin Infect Dis; 2008 Oct; 47(7):984-5. PubMed ID: 18778234
[No Abstract] [Full Text] [Related]
5. [Approval of a new nucleoside. Component of complete once daily regimen].
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():91. PubMed ID: 15373067
[No Abstract] [Full Text] [Related]
6. [One year with Atripla. Changeover to complete HIV therapy in a single tablet has proven successful].
Warpakowski A
MMW Fortschr Med; 2009 Apr; 151(18):54-5. PubMed ID: 19769077
[No Abstract] [Full Text] [Related]
7. Two-once-daily fixed-dose NRTI combinations for HIV.
Med Lett Drugs Ther; 2005 Feb; 47(1203):19-20. PubMed ID: 15767973
[TBL] [Abstract][Full Text] [Related]
8. 144-week data released on Gilead's study 934.
AIDS Patient Care STDS; 2007 Aug; 21(8):603-4. PubMed ID: 17902243
[No Abstract] [Full Text] [Related]
9. Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients.
Rousseau FS; Wakeford C; Mommeja-Marin H; Sanne I; Moxham C; Harris J; Hulett L; Wang LH; Quinn JB; Barry DW;
J Infect Dis; 2003 Dec; 188(11):1652-8. PubMed ID: 14639535
[TBL] [Abstract][Full Text] [Related]
10. Antiretroviral activity of emtricitabine, a potent nucleoside reverse transcriptase inhibitor.
Richman DD
Antivir Ther; 2001 Jun; 6(2):83-8. PubMed ID: 11491420
[No Abstract] [Full Text] [Related]
11. [First line therapy. Tenofovir DF/emtricitabine--the potent backbone].
MMW Fortschr Med; 2008 Apr; 150 Spec No 1():12-4. PubMed ID: 19024908
[No Abstract] [Full Text] [Related]
12. 96-week CASTLE data show similar efficacy results.
AIDS Patient Care STDS; 2008 Nov; 22(11):918. PubMed ID: 19043840
[No Abstract] [Full Text] [Related]
13. [Simply convincing. New fixed combination for HIV therapy].
MMW Fortschr Med; 2005 Apr; 147 Spec No 1():20-3. PubMed ID: 16385865
[No Abstract] [Full Text] [Related]
14. [Medication change due to side effects or possible long-term complications. Side effect management with vision].
Sankawa Y
MMW Fortschr Med; 2009 Apr; 151(18):35. PubMed ID: 19769072
[No Abstract] [Full Text] [Related]
15. The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients.
Chetchotisakd P
Expert Rev Anti Infect Ther; 2009 Sep; 7(7):801-5. PubMed ID: 19735222
[TBL] [Abstract][Full Text] [Related]
16. [Improved long-term success. New nucleoside for once daily combinations].
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():31-3. PubMed ID: 15373043
[No Abstract] [Full Text] [Related]
17. Emtricitabine: a new treatment option for simplified antiretroviral therapy.
Molina JM
AIDS Read; 2003 Sep; ():S16-21. PubMed ID: 14601555
[No Abstract] [Full Text] [Related]
18. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
Delfraissy JF; Flandre P; Delaugerre C; Ghosn J; Horban A; Girard PM; Norton M; Rouzioux C; Taburet AM; Cohen-Codar I; Van PN; Chauvin JP
AIDS; 2008 Jan; 22(3):385-93. PubMed ID: 18195565
[TBL] [Abstract][Full Text] [Related]
19. Selection of drug-resistant HIV-1 during the early phase of viral decay is uncommon in treatment-naïve patients initiated on a three- or four-drug antiretroviral regimen including lamivudine.
Bergroth T; Ekici H; Gisslén M; Loes SK; Goh LE; Freedman A; Lampe F; Johnson MA; Sönnerborg A
J Med Virol; 2009 Jan; 81(1):1-8. PubMed ID: 19031460
[TBL] [Abstract][Full Text] [Related]
20. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
Rey D; Hoen B; Chavanet P; Schmitt MP; Hoizey G; Meyer P; Peytavin G; Spire B; Allavena C; Diemer M; May T; Schmit JL; Duong M; Calvez V; Lang JM
J Antimicrob Chemother; 2009 Feb; 63(2):380-8. PubMed ID: 19036752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
